

## Surgical Infection Society Statement on EBOLA

Surgeons in North America need to be prepared to evaluate and operate on patients with the EBOLA virus. In the limited literature that exists, most clinical observations include abdominal pain.<sup>1-6</sup> The first case of EBOLA diagnosed in the United States presented with a constellation of symptoms that included abdominal pain.

We can anticipate that surgeons will be consulted for abdominal pain in patients who have EBOLA. Additionally, surgical emergencies not related to the EBOLA virus will arise in patients with EBOLA and perhaps those with suspected EBOLA. The effect of EBOLA on surgical outcomes is not known, however because of the rapid progression of the infection, it is anticipated that the prognosis after surgery will remain guarded.

There is experience with surgery in other communicable diseases. The American College of Surgeons "Statement on the Surgeon and HIV Infection" recommends that using the highest standards of infection control, surgeons are ethically obligated to render care to HIV-infected patients.<sup>7</sup> EBOLA appears to be more easily transmitted than HIV, but the CDC has recommendations for infection control by healthcare workers aiding EBOLA patients, to include standard, contact, and droplet precautions.<sup>8</sup> Additionally, the WHO has published guidelines on protective measures for medical staff.<sup>9</sup>

There is research into existing medications that may inhibit cell entry for the EBOLA virus. In cell culture, amiodarone, verapamil, and dronedarone inhibit cell entry by filovirus, which includes the EBOLA virus.<sup>10</sup> There is no clinical evidence regarding the effect of these drugs on acquisition of EBOLA in healthcare workers who have been exposed. The gravity of the situation may warrant a clinical trial.

There is little information on the critical care management of EBOLA patients. In one animal study, EBOLA caused hypotension, tachycardia, tachypnea, acidosis, and renal failure. Treatment with normal saline attenuated the renal failure, but did not affect mortality.<sup>11</sup> At present, no specific recommendations can be made regarding how to manage patients with EBOLA who are critically ill.

While we are faced with an incompletely understood challenge, the basic principles of compassionate care using the best available science apply to the current situation. Surgeons must remain abreast of the latest developments in order to be prepared to safely care for patients with EBOLA and surgical problems.

1. Ebola haemorrhagic fever in Zaire, 1976. Bulletin of the World Health Organization 1978;56:271-93.
2. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bulletin of the World Health Organization 1978;56:247-70.
3. Sureau PH. Firsthand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire. Reviews of infectious diseases 1989;11 Suppl 4:S790-3.
4. Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. The Journal of infectious diseases 1999;179 Suppl 1:S1-7.
5. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. The Journal of infectious diseases 1999;179 Suppl 1:S48-53.
6. Mbonye A, Wamala J, Winyi K, Tugumizemo V, Aceng J, Makumbi I. Repeated outbreaks of viral hemorrhagic fevers in Uganda. African health sciences 2012;12:579-83.
7. Statement on the Surgeon and HIV Infection. 2004. (Accessed 10/2/2014, 2014, at <http://www.facs.org/about-acs/statements/13-hiv-infection>.)
8. Evaluating Patients for Possible Ebola Virus Disease: Recommendations for Healthcare Personnel and Health Officials. 2014. (Accessed 10/2/2014, 2014, at <http://emergency.cdc.gov/han/han00371.asp>.)
9. Ebola: Protective measures for medical staff. 2014. (Accessed 10/2/2014, 2014, at <http://www.who.int/csr/disease/ebola/protective-measures-staff/en/>.)
10. Gehring G, Rohrmann K, Atenchong N, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. The Journal of antimicrobial chemotherapy 2014;69:2123-31.
11. Kortepeter MG, Lawler JV, Honko A, et al. Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. The Journal of Infectious Diseases 2011;204 Suppl 3:S1000-10.